Cardio Diagnostics Holdings Inc Total Liabilities
Cardio Diagnostics Holdings Inc total liabilities. Based on the latest financial reports, Cardio Diagnostics Holdings Inc (CDIO) has total liabilities worth $499.78K USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Cardio Diagnostics Holdings Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Cardio Diagnostics Holdings Inc (2020–2025)
Total liabilities of Cardio Diagnostics Holdings Inc from 2020 to 2025. This chart illustrates how Cardio Diagnostics Holdings Inc's total liabilities have evolved over time, based on quarterly financial data.
Cardio Diagnostics Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Cardio Diagnostics Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Helios Energy Ltd
AU:HE8
|
Australia | AU$1.91 Million |
|
MRG Metals Ltd
AU:MRQ
|
Australia | AU$182.35K |
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
USA | $4.92 Million |
|
Auddia Inc
NASDAQ:AUUD
|
USA | $853.85K |
|
Hybrid Financial Services Limited
NSE:HYBRIDFIN
|
India | Rs108.44 Million |
|
HLT Global Bhd
KLSE:0188
|
Malaysia | RM76.94 Million |
|
Ecoslops SA
PA:ALESA
|
France | €19.77 Million |
|
Brilliant Future AB
ST:BRILL
|
Sweden | Skr46.11 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Cardio Diagnostics Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CDIO total asset value.
Liquidity & Leverage Metrics
Cardio Diagnostics Holdings Inc Total Liabilities Ratios Explained
Cardio Diagnostics Holdings Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cardio Diagnostics Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cardio Diagnostics Holdings Inc (2020–2025)
The table below shows the annual total liabilities of Cardio Diagnostics Holdings Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $793.06K | -25.01% |
| 2024-12-31 | $1.06 Million | -29.70% |
| 2023-12-31 | $1.50 Million | -22.77% |
| 2022-12-31 | $1.95 Million | +5648.18% |
| 2021-12-31 | $33.88K | -91.22% |
| 2020-12-31 | $386.01K | -- |
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more